MarketCap
Facebook
X
Telegram
PMV Pharmaceuticals Net Income | PMVP
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income PMV Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -77.7 M | -58.9 M | -69 M | -73.3 M | -57.8 M | -34.4 M | -25.4 M | -17.5 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -17.5 M | -77.7 M | -51.8 M |
Quarterly Net Income PMV Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18 M | -21.1 M | -21.2 M | -17.4 M | - | -19.2 M | -1.21 M | -15.3 M | - | -16.6 M | -17.4 M | -19.1 M | - | -18.2 M | -17.3 M | -18.4 M | - | -15 M | -12.9 M | -11.6 M | - | -8.76 M | -7.97 M | -7.26 M | - | -6.18 M | -6.13 M | -6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.21 M | -21.2 M | -13.7 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Teva Pharmaceutical Industries Limited
TEVA
|
1.41 B | $ 42.32 | 1.33 % | $ 48.5 B |  Israel |
 |
RedHill Biopharma Ltd.
RDHL
|
-8.27 M | $ 0.43 | 0.45 % | $ 5.3 B | Israel |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M |  USA |
 |
Unity Biotechnology
UBX
|
-26 M | - | -33.41 % | $ 3.37 M | USA |
 |
iTeos Therapeutics
ITOS
|
-134 M | - | - | $ 411 M | USA |
 |
Shattuck Labs
STTK
|
-48.8 M | $ 4.59 | 2.78 % | $ 319 M | USA |
 |
Seelos Therapeutics
SEEL
|
-37.9 M | - | -47.76 % | $ 6.27 M | USA |
 |
Evogene Ltd.
EVGN
|
-7.83 M | $ 0.28 | -16.14 % | $ 2.2 M | Israel |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Protara Therapeutics
TARA
|
-57.4 M | $ 2.33 | 9.15 % | $ 99.8 M | USA |
 |
Trevi Therapeutics
TRVI
|
-42.8 M | $ 14.33 | 11.87 % | $ 1.93 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-10.3 M | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Fennec Pharmaceuticals
FENC
|
-9.74 B | $ 9.79 | 4.26 % | $ 280 M | USA |
 |
Kiromic BioPharma
KRBP
|
-26.9 M | - | 6.61 % | $ 3.08 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-15.9 M | $ 3.92 | -2.24 % | $ 1.74 M | USA |
 |
Calithera Biosciences
CALA
|
-39.6 M | - | -10.95 % | $ 876 K | USA |
 |
United Therapeutics Corporation
UTHR
|
1.33 B | $ 562.14 | -0.63 % | $ 24.9 B | USA |
 |
Vericel Corporation
VCEL
|
16.5 M | $ 54.56 | 5.36 % | $ 2.75 B | USA |
 |
Veracyte
VCYT
|
66.4 M | $ 24.1 | 0.42 % | $ 1.89 B | USA |
|
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-74.9 M | $ 3.72 | 0.95 % | $ 236 M | USA |
 |
Molecular Templates
MTEM
|
-8.12 M | - | -23.43 % | $ 495 K | USA |
 |
Vanda Pharmaceuticals
VNDA
|
-220 M | $ 3.82 | 6.27 % | $ 225 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
-17.9 M | $ 3.22 | 4.21 % | $ 34.3 M | USA |
 |
Viridian Therapeutics
VRDN
|
-343 M | $ 28.47 | -0.28 % | $ 2.9 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-69.9 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
VistaGen Therapeutics
VTGN
|
-69.7 M | $ 0.17 | 3.45 % | $ 6.47 M | USA |
 |
Voyager Therapeutics
VYGR
|
-120 M | $ 1.86 | 8.14 % | $ 109 M | USA |
 |
CohBar
CWBR
|
-12.2 M | - | -15.44 % | $ 2.2 M | USA |
 |
NeuBase Therapeutics
NBSE
|
-4.37 M | - | -1.56 % | $ 12.3 M | USA |
 |
Gossamer Bio
GOSS
|
-170 M | $ 9.77 | 3.72 % | $ 2.23 B | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-195 M | - | - | $ 2.18 B | USA |
 |
GeoVax Labs
GOVX
|
-21.5 M | $ 0.16 | -5.0 % | $ 153 K | USA |
 |
Arena Pharmaceuticals
ARNA
|
-616 M | - | -6.81 % | $ 3.04 B | USA |
 |
Scopus BioPharma
SCPS
|
-11.6 M | - | -48.37 % | $ 3.71 M | USA |
 |
Annovis Bio
ANVS
|
-28.9 M | $ 0.82 | 23.72 % | $ 16.9 M | USA |
 |
scPharmaceuticals
SCPH
|
-85.1 M | - | - | $ 218 M | USA |
 |
Xeris Pharmaceuticals
XERS
|
554 K | $ 15.08 | 15.29 % | $ 2.42 B | USA |
 |
X4 Pharmaceuticals
XFOR
|
-79.2 M | $ 3.15 | 2.61 % | $ 133 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
-47.1 M | - | - | $ 105 M | USA |
 |
Athersys
ATHX
|
-72.5 M | - | 3.77 % | $ 22.4 M | USA |
 |
Zai Lab Limited
ZLAB
|
-176 M | $ 25.49 | 12.77 % | $ 27.9 B |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
-137 M | $ 1.71 | 2.05 % | $ 123 M | USA |
 |
Zoetis
ZTS
|
2.67 B | $ 79.51 | -3.21 % | $ 35.3 B | USA |
 |
Global Blood Therapeutics
GBT
|
-303 M | - | - | $ 4.62 B | USA |
 |
Inozyme Pharma
INZY
|
-102 M | - | - | $ 207 M | USA |
 |
Idera Pharmaceuticals
IDRA
|
-23.4 M | - | -23.04 % | $ 26.6 M | USA |
 |
NanoString Technologies
NSTG
|
-160 M | - | -37.43 % | $ 5.1 M | USA |
 |
Humanigen
HGEN
|
-70.7 M | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
-573 M | - | -29.58 % | $ 126 M | USA |